![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis
|
|
|
IDweek 2020 Oct 21-25 virtual
Reported by Jules Levin
Keith Dunn,1 Bryan Baugh,2 Nika Bejou,1,* Donghan Luo,3 Jennifer Campbell,1 David Anderson1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA; 3Janssen Research & Development, LLC, Titusville, NJ, USA.
![1026201](../images/102520/102620-5/1026201.gif)
![1026202](../images/102520/102620-5/1026202.gif)
![1026203](../images/102520/102620-5/1026203.gif)
![1026204](../images/102520/102620-5/1026204.gif)
![1026205](../images/102520/102620-5/1026205.gif)
![1026206](../images/102520/102620-5/1026206.gif)
![1026207](../images/102520/102620-5/1026207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|